Clinical Trials Browser

Phase 2 × bavituximab × 90 days × Clear all

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2 Active not recruiting

7 enrolled 11 charts

Carcinoma, Squamous Cell

NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

35 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular